Evidence map›Paper›PMID 30478476›Full record

ReviewUrolithiasis2019

Empiric therapy for kidney stones.

David S Goldfarb

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Urolithiasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Breaking the Cycle of Recurrent Calcium Stone Disease.Advances in kidney disease and health · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David S GoldfarbNephrology Division, NYU Langone Health, New York, NY, USA. david.goldfarb@nyulangone.org.ORCID http://orcid.org/0000-0002-9215-1273
NYU Langone Health · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
National Institute of Diabetes and Digestive and Kidney Diseases U54DK083908-01NIDDK NIH HHS U54 DK083908
6 · The paper itself

Abstract

Careful phenotyping of patients to classify those with kidney stones has a long and important history in revealing the chemical basis for stone formation. Advances in our genetic understanding of kidney stones will lead to incredible insights regarding the pathophysiology of this common disorder. At this time, both evaluation of urine chemistry and genotyping of patients are extremely useful in the setting of a university and research-based kidney stone clinic. For much of the world, in a more clinically focused setting, these techniques are neither available nor absolutely necessary. Careful implementation of an empiric prescription based on stone composition would have an important effect to reduce stone recurrence in the world's many stone formers. Increased fluid intake, generic dietary manipulations, and prescription of potassium citrate and thiazides are all appropriate empiric therapies for people with calcium and uric acid kidney stones.

Indexed as

CalciumDietary Approaches To Stop HypertensionDiet, Sodium-RestrictedFluid TherapyGenetic TestingHumansKidney CalculiPotassium CitrateRecurrenceThiazidesTreatment OutcomeUric AcidCalciumPotassium CitrateThiazidesUric AcidDietGeneticsKidney calculiNephrolithiasisPotassium citrateThiazidesUric acidUrolithiasis

Identifiers

PMID30478476
PMCPMC6361718
OpenAlexW2903458970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.